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Abstract
Background: α-Synuclein has been proposed as a potential biomarker for Alzheimer’s disease (AD) and amnestic
mild cognitive impairment (aMCI). However, results from α-synuclein measurements in cerebrospinal fluid (CSF)
have been inconclusive, and to our knowledge, longitudinal studies of changes prior to the AD diagnosis have not
been investigated.
Methods: Levels of α-synuclein at baseline and after one and two years were measured in CSF, by enzyme-linked
immunosorbent assay. Twenty-six patients with early AD (AD-AD), 48 patients with aMCI, subdivided as 23 that
developed AD during follow-up (MCI-AD), and 25 that did not (MCI-MCI), and 25 healthy control individuals, were
included. One-way ANOVA was applied to compare mean α-synuclein baseline values between all four study
groups, and a linear mixed model was used to compare mean change over time between the three patient groups.
Linear associations between α-synuclein and amyloid-β 1–42 (Aβ42), amyloid-β 1–40 (Aβ40), total tau and
phosphorylated tau were also examined.
Results: A large variation in individual α-synuclein CSF levels was observed, particularly in the MCI-AD group.
No significant differences were found in mean α-synuclein levels between all the study groups at baseline. When
using a linear mixed model, no significant differences were found at follow-up for estimated mean changes
between the patient groups. MCI-AD patients with short duration of symptoms prior to inclusion in the study
(≤2 years) had considerably higher mean CSF α-synuclein levels compared to patients with a longer symptom
duration (802.2 vs. 442.8 pg/mL, p = 0.01). No such difference was seen in the MCI-MCI or AD-AD groups. Significant
linear associations (p < 0.0005) between α-synuclein and Aβ40, total tau and phosphorylated tau were found.
Conclusion: The observed difference in mean CSF α-synuclein level according to duration of symptoms in the
MCI-AD group, may be an indication of changes related to disease progression. However, the lack of significant
differences between groups, as well as the large individual variation in CSF levels of α-synuclein in the present
study, suggest that α-synuclein is not a useful biomarker for AD.
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Background
Alzheimer’s disease (AD) is the most common cause of
dementia, and is considered to be a slow progressive
heterogeneous disorder resulting in death of neurons and
progressive cognitive decline. The disease is preceded by a
prodromal phase, mild cognitive impairment, which is
usually amnestic (aMCI) [1]. The ability to diagnose pa-
tients at an early stage before dementia develops is urgent.
Classical AD neuropathology demonstrates amyloid
plaques and neurofibrillary tangles [2, 3], and cerebrospinal
fluid (CSF) levels of amyloid-β 1–42 (Aβ42), total tau
(t-tau), and phosphorylated tau (p-tau) are promising
diagnostic biomarkers. Patients with AD usually have
lower CSF levels of Aβ42, and higher levels of tau
compared to healthy controls. Measurement of these
biomarkers in CSF is included in new suggested criteria
as complementary to a clinical diagnosis [4]. The most
abundant amyloid form, Aβ40, does not distinguish as
well between patients with AD and healthy control
individuals [5, 6].
In addition to plaques and tangles, up to 60 % of
patients with AD also show evidence of Lewy body path-
ology [7–11], traditionally considered a hallmark of
synucleinopathies such as Parkinson’s disease and demen-
tia with Lewy bodies [12]. The presynaptic α-synuclein
protein [13] is the major constituent of Lewy bodies and
Lewy neurites [14], and is found in CSF at measurable
levels [15, 16]. In most studies, patients with AD or aMCI
show increased CSF levels of α-synuclein compared to
healthy controls [17–21], perhaps due to release from
damaged neuronal cell bodies and other processes during
neurodegeneration [17]. However, no difference [22, 23],
or a reduced level [24] have also been found. In CSF from
patients with AD α-synuclein has shown strong correl-
ation with t-tau and p-tau in some studies [19–21], but
not all [25]. Moreover, an interdependent effect between
α-synuclein, tau and amyloid-β in neurodegeneration has
been proposed [26]. Results from experimental research
on transgenic DLB-AD mice have indicated that α-
synuclein, tau and amyloid-β proteins may act synergistic-
ally by mutually accelerating their accumulation and
aggregation, leading to rapid cognitive decline [27].
α-Synuclein has been proposed as an additional CSF
biomarker for AD and aMCI [17, 20]. To our knowledge,
no previous studies have investigated changes in α-
synuclein levels in CSF during the time window when the
disease progresses from aMCI to AD. The aim of the
present study was to evaluate the diagnostic potential of
CSF levels of α-synuclein in the early stages of AD. CSF
levels of α-synuclein were measured in patients with aMCI
at the time of inclusion and during a two-year follow-up
period with and without progression to AD, as well as in
patients with AD from baseline and during two years of
follow-up, and in healthy control individuals (baseline
levels only). A potential association between α-synuclein
and the APOE ɛ4 allele (the greatest genetic risk factor for
AD [28]) was investigated, as well as potential correlations
between α-synuclein and other known biomarkers for AD.
Method
Study participants
The present study included a total of 74 patients and
25 controls enrolled in a two-year follow-up study
from the summer of 2009. All subjects were ethnic
Norwegians between 53 and 78 years of age and recruited
through the Department of Neurology, University Hospital
of Trondheim, by two neurologists (SBS or GRG).
Neurological examination was performed on both pa-
tient and control groups, including the Mini Mental
State Examination (MMSE) [29] and the Ten-Word
Test with delayed recall as taken from ADAS Cog [30],
as well as cerebral MRI at 3 T at baseline and after two
years. APOE genotyping was performed on blood sam-
ples according to the method described elsewhere [31].
General exclusion criteria were insufficient sight and
hearing to complete the cognitive testing, a present
psychiatric or malignant disease, use of anti-coagulating
medication, or high alcohol consumption.
Patients diagnosed with aMCI or AD
At inclusion 26 patients were diagnosed with early AD
(National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) criteria
[32]), and 48 with aMCI (The International Working
Group on Mild Cognitive Impairment Criteria [33]).
Patients returned to the hospital one and two years after
inclusion, with lumbar puncture and neuropsychological
tests performed on each occasion. A few patients missed
certain time-points of lumbar puncture. During follow-up,
23 of the aMCI patients kept their initial diagnosis (desig-
nated MCI-MCI), while 25 developed AD (designated
MCI-AD). Patients diagnosed with AD from baseline
comprised the AD-AD group. These three patient groups
were compared in the statistical analyses. A detailed over-
view of the clinical work-up is described elsewhere [34].
Healthy controls
Twenty-five healthy elderly volunteers were recruited as
controls from societies for retired people in central
Norway, or caregivers not genetically related to the
patients. Lumbar puncture was performed at inclusion,
whereas neuropsychological examination was performed
at both inclusion and after two years. Control individuals
were assessed as being healthy for their age without
signs of neurological disorders, and without first-degree
relatives with dementia.
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Sampling and analysis of CSF
Patients and healthy controls underwent lumbar punc-
ture, usually at the L4/L5 intervertebral space, and CSF
samples were obtained as described previously [34].
Briefly, 1 mL aliquots of CSF were collected directly into
Corning 2 mL polypropylene cryovials immersed in ice-
water, and frozen within 30 min of lumbar puncture and
stored at −80 °C [35, 36]. Only three CSF samples from
patients were centrifuged prior to freezing due to
contamination from blood. Erythrocyte counts in the
remaining samples were (mean ± SD) 1.6 ± 2.8/μL (overall
range 0–17 erythrocytes/μL). The albumin quotient (QA
= albumin in CSF/albumin in plasma) [37] was calculated
for all samples. All samples were transferred to −20 °C ap-
proximately one week prior to analysis, and were slowly
thawed in ice-water on the morning of analysis. The CSF
samples were analyzed by commercially-available enzyme-
linked immunosorbent assay (ELISA) monoplex kits; α-
synuclein (Invitrogen: cat.no KHB0061), Aβ1-42 (Innoge-
netics: Aβ42, cat. no. 80324), total tau protein (t-tau, cat.
no. 80323), 181-phosphorylated tau (p-tau, cat. no.
80317), and Aβ-40 (IBL International: cat. no. 81015). All
assays were run according to the manufacturers’ instruc-
tions. Patient and healthy control samples were run on the
same plates, in duplicate and averaged. An internal control
was run on five out of seven α-synuclein ELISA plates,
giving an inter-assay CV of 10.2 %, while the intra-assay
CV was 2.9 % (n = 7). CV values for the core biomarkers
are given elsewhere [34], but biomarker results were
unknown at the time of clinical diagnosis. None of the
individuals were excluded from the study due to increased
hemoglobin levels in the samples, which is known to be a
confounding factor in α-synuclein quantification in CSF,
resulting in artificially increased values [18].
Statistical analyses
The four study groups (AD-AD, MCI-AD, MCI-MCI,
healthy control individuals) were compared with respect
to categorical demographic and clinical characteristics at
the time of inclusion by means of the chi-square tests
(overall and pairwaise comparisons). One-way ANOVA
was conducted to compare characteristics measured on
a continuous scale, and also mean baseline values of α-
synuclein, Aβ42, Aβ40, t-tau and p-tau. In pairwise
comparison between groups, the least significant
difference (LSD) procedure was applied, adjusting the
nominal significance level to 1 %. A linear mixed model
with subject as random factor, and with interaction
terms added, was applied to compare mean changes in
α-synuclein levels during follow-up (measurements at
inclusion, and after 1 and 2 years, respectively) between
the three patients groups. Both non-linear (categorical)
and linear (per year) time patterns were considered.
Moreover, linear associations between α-synuclein and
other biomarkers (Aβ42, Aβ40, t-tau, p-tau) were examined
with Pearson’s correlation coefficient and linear regression
analysis. The determination coefficient (R2) is reported as
the measure of percent explained variance in the linear
regression model.
Results
Demographic and clinical characteristics, and core bio-
markers at time of inclusion as well as APOE ɛ4 allele
data are shown in Table 1. The study groups did not dif-
fer significantly in gender, mean age at inclusion, mean
age at onset, or mean duration since the first symptom
for the respective diagnosis. The AD-AD and the MCI-
AD groups had a larger proportion of subjects with
MMSE test scores below 27 compared to healthy
controls (p ≤ 0.010). The patient groups also differed
significantly; patients in the AD-AD group more often
had a score below 27 compared with the MCI-MCI or
MCI-AD groups, and a larger proportion of the patients
in the MCI-AD group had a low score compared with
patients in the MCI-MCI group. Similarly, all the patient
groups had reduced delayed recall for the Ten-word Test
(all p < 0.0005) compared with healthy control individ-
uals, with the AD-AD and MCI-AD groups having
poorer recall than the MCI-MCI group (both p ≤ 0.001).
The proportion of APOE ε4 allele carriers differed
significantly between the study groups (p < 0.0005), with
the patients having considerably higher proportions of
carriers than healthy control individuals.
Mean baseline concentrations of Aβ42, t-tau and p-tau
measured in CSF differed significantly between the four
groups (all p < 0.0005), whereas no significant difference
in Aβ40 was found (p = 0.24). Aβ42 concentration levels
were lower in all patient groups compared to control
individuals (all p < 0.0005), while no significant differ-
ences were found when comparing the patient groups
against each other. A significantly higher mean level of
t-tau and p-tau was found in the MCI-AD and AD-AD
groups compared to healthy controls (all p < 0.0005), as
well as compared to MCI-MCI (all p ≤ 0.003). No signifi-
cant difference in these biomarkers was found between
the AD-AD and MCI-AD groups.
α-Synuclein levels in CSF at baseline, and during
follow-up of patients with AD or aMCI
One patient from the MCI-AD group had a considerably
elevated CSF α-synuclein concentration at baseline, and
another at two years (though both were in the range of
the kit). The albumin quotient for these two patients
(and patients in general), did not indicate a disturbance
of the blood–brain barrier [37] (data not shown). The
analysis of changes in α-synuclein was first carried out
with the two extreme values excluded. Mean baseline
concentrations and standard deviations of α-synuclein in
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all study groups, and mean values after 1 and 2 years in
the three patient groups are shown in Table 2a. The
highest baseline mean level of α-synuclein measured in
CSF was found in the MCI-AD group, with the other
groups having approximately similar mean levels, lowest
for the AD-AD group (p = 0.26, test for overall difference
between groups). The individual variation was large in
all study groups, but the standard deviation was larger in
the two MCI groups than in the AD-AD and the control
groups (Table 2a). The difference in mean α-synuclein
baseline level became more pronounced when the two
extreme values were included in the analysis (Additional
file 1: Table S1a). The overall test for difference between
the four study groups was then closer to statistical
significance (p = 0.08), and the test for difference be-
tween the MCI-AD and the AD-AD groups was signifi-
cant at the 5 % level, but not at the 1 % level (p = 0.019).
Individual time patterns of α-synuclein levels in the
three patient groups are shown in Fig. 1a-c. Most patients
had levels between 200–750 pg/mL. Except for one
patient in the AD-AD group, values above 1000 pg/mL
occurred only in the MCI-MCI and MCI-AD groups. A
decrease in α-synuclein during the first year of follow-up
was seen in all groups (extreme values excluded), but was
more pronounced in the MCI-AD group than in the AD-
AD and MCI-MCI groups (Table 2b, mean reduction of
16.7 vs. 11.4 and 9.0 pg/mL, respectively). In the MCI-AD
group, α-synuclein values decreased also in the second
year, in contrast to the pattern seen in the AD-AD and
MCI-MCI groups (Table 2b). However, no significant
changes in α-synuclein over time were seen within any of
the groups, and the mean reduction over time did not
differ between the groups (p = 0.93 and p = 0.67, test for
categorical and linear interaction, respectively). Moreover,
the mean α-synuclein levels did not differ significantly
between the groups either after one year (p = 0.23) or after
two years (p = 0.33). The mean α-synuclein values
predicted on the basis of the linear mixed model fitted
observed data rather well (Fig. 1d). In the analyses with
the two extreme values included, the mean reduction in
α-synuclein levels over time in the MCI-AD group was
considerably more pronounced (Additional file 1: Table
S1b). Nevertheless, no significant differences were found,
either within or between the three patient groups.











Female 13 (50.0) 14 (56.0) 10 (43.5) 15 (60.0)
Male 13 (50.0) 11 (44.0) 13 (56.5) 10 (40.0) 0.68
Age at inclusion
(mean ± SD) 64.2 ± 6.2 63.7 ± 4.4 65.4 ± 6.1 67.3 ± 5.0 0.10
Age at onset
(mean ± SD) 61.3 ± 6.3 61.0 ± 4.5 62. 9 ± 6.7 na 0.50
Duration of symptoms
(mean ± SD) 3.0 ± 1.8 2.8 ± 1.0 2.9 ± 2.3 na 0.94
Ten Word Test (delayed recall)
(mean ± SD) 1.6 ± 1.6 2.1 ± 1.8 3.8 ± 1.8 7.0 ± 1.7 <0.0005
MMSE, n (%)
< 27 24 (92.7) 12 (48.0) 4 (17.4) 0 (0)
≥ 27 2 (7.7) 13 (52.0 ) 19 (82.6) 25 (100.0) <0.0005
APOE ɛ4 carrier
n (%) 21 (80.8) 19 (76.0) 12 (54.5) 7 (28.0) <0.0005
Aβ42 (pg/mL) 498.7 ± 208.5 535.0 ± 176.3 647.7 ± 344.5 1080.5 ± 266.1 <0.0005
Aβ40 (pg/mL) 15265 ± 5386 15003 ± 4453 14216 ± 8073 18207 ± 6595 0.24
T-tau (pg/mL) 769.0 ± 405.4 733.7 ± 515.5 369.0 ± 345.6 297.9 ± 129.9 <0.0005
P-tau (pg/mL) 96.6 ± 35.6 90.6 ± 33.8 60.1 ± 27.8 57.0 ± 16.8 <0.0005
AD-AD patients diagnosed with Alzheimer’s disease at inclusion, MCI-AD patients with amnestic mild cognitive impairment at inclusion, progressing to AD during
2 years of follow-up, MCI-MCI patients with MCI at inclusion keeping their initial diagnosis during 2 years of follow-up, CTR healthy control individuals
MMSE mini mental state examination, Ten-Word Test from ADAS Cog
T-tau total tau, P-tau phosphorylated tau
APOE genotype missing for one MCI-MCI patient
Na not applicable
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Table 2 a) Observed group mean values (± SD) for α-synuclein at inclusion (baseline), and after one and two years, and b) predicted
mean value (95 % CI) at baseline, together with estimated mean change (95 % CI) from baseline valuesa
α-synuclein (pg/mL)
AD-AD MCI-AD MCI-MCI CTR p-valueb p-valuec
a)
Baseline 494.4 ± 275.0 671.8 ± 383.1 568.6 ± 390.5 514.4 ± 263.1 0.26
1 year 466.0 ± 324.8 650.9 ± 458.4 559.5 ± 339.6 na
2 years 439.4 ± 285.5 587.4 ± 386.5 565.7 ± 393.3 na
b)
Baseline 477.3 (333.3,621.4) 661.7 (514.3,809.0) 568.6 (415.4,721.2) 0.22
Mean change 0.93
After 1 year −11.3 (−76.9, 54.3) −16.7 (−85.8, 52.3) −9.0 (−77.8, 59.7) 0.23
After 2 years −9.0 (−77.7, 59.7) −42.0 (−112.2, 28.1) 0.02 (−69.9, 69.9) 0.33
Linear trendd −4.6 (−38.6, 29.4) −21.0 (−55.7, 13.7) −0.09 (−34.6, 34.5) 0.67
Na not applicable
aResults based on linear mixed model with subject as random factor (two extreme values excluded)
bF-test for overall difference in mean α-synuclein levels between study groups (one-way ANOVA), or between patient groups (LMM)
cF-test for heterogeneity in mean change over time in α-synuclein between patient groups (categorical and linear interaction, respectively)
dMean change per year, based on model with linear time trend
Fig. 1 a-c: Individual α-synuclein levels (x-axis: pg/mL) in CSF over time in each patient group. The group mean value at inclusion (one extreme value
excluded in the MCI-AD group) is indicated by a bold line. d: mean values, observed (filled circle) and predicted (open circle), of α-synuclein levels at
each time point (two extreme values excluded, one at baseline and one after 2 years). The mean value for controls (baseline only) is shown as a
dashed line
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Mean α-synuclein CSF levels and duration of symptoms
Patients were included in the present study between one
and seven years after onset of the first symptom related to
aMCI or AD. In view of the large variation in individual
α-synuclein levels at baseline, the mean α-synuclein level
at time of inclusion in the study was compared between
groups defined by duration of symptoms prior to inclusion
(1–2 years vs. ≥ 3 years). In the MCI-AD group, those
with the shortest duration of symptoms had significantly
higher mean α-synuclein CSF concentration (802.2 pg/
mL, confidence interval: 553.9 - 1051.5 pg/mL) than pa-
tients in the group with longer duration (442.8 pg/mL,
confidence interval: 320.3 - 565.4 pg/mL), two sample t-
test, p = 0.01, extreme value at baseline excluded. No sig-
nificant differences were found according to duration of
symptoms in the MCI-MCI or AD-AD groups.
Association between α-synuclein and the core AD
biomarkers
In CSF samples from healthy control individuals, Aβ40, t-
tau and p-tau all showed strong linear associations with
CSF α-synuclein (determination coefficient R2 in range
57.3-61.8 %, p < 0.0005) whereas the association with
Aβ42 was weaker (R2 of 24.7 %). In a combined analysis of
all patient groups, the association between baseline CSF
α-synuclein and Aβ40 was similar to that observed in
healthy individuals (Fig. 2b), whereas the strength of linear
association with t-tau and p-tau was slightly weaker
(Fig. 2c and d, R2 = 41.6 % and 42.3 %, respectively, p <
0.0005). No significant association was found between
Aβ42 and α-synuclein (p = 0.69), Fig. 2a. In a model with
mutual adjustment for all these biomarkers, all factors to-
gether explained 67.3 % of the variation in α-synuclein,
but only Aβ40 and p-tau contributed significantly. The
direction of linear association between each biomarker
and α-synuclein was consistently observed within all four
study groups, except that Aβ42 was negatively correlated
in the MCI-AD group (Pearson’s correlation coefficient
−0.325) and positively correlated in the other study groups
(Pearson’s correlation coefficient in range 0.075 – 0.499).
The opposite direction of association with Aβ42 in the
patient groups probably explains the lack of association in
combined analysis of all patients.
Associations between α-synuclein and APOE ɛ4
The mean concentration of α-synuclein did not differ
significantly between APOE ɛ4 carriers and non-carriers
in any group (Additional file 2 Table S2), though a more
pronounced difference was detected in the MCI-AD
group. In this patient group, carriers of APOE ɛ4 had a
mean CSF α-synuclein level of 887.1 ± 692.9 pg/mL
whereas non-carriers had a mean level of 442.3 ±
181.1 pg/mL. However, the difference was not statisti-
cally significant.
Discussion
To our knowledge this is the first study to investigate
CSF levels of α-synuclein during the transition from
aMCI to AD. Patients with aMCI or AD showed com-
paratively stable levels of α-synuclein from inclusion and
over a two year period. Except for a slightly higher base-
line concentration of α-synuclein in the MCI-AD group,
no differences were observed, either between the patient
groups, or in comparisons with healthy control individ-
uals. Although some measured levels were high, albumin
quotients did not suggest leakage of α-synuclein from
blood as being responsible for these high levels. Both the
observed levels of α-synuclein, and lack of association
with the APOE ɛ4 allele are in accordance with previous
findings [17, 19, 21, 23]. Our results do not indicate
marked differences in mean α-synuclein concentrations
between the four groups, and the considerable variation
in measured levels makes it difficult to find subtle differ-
ences between groups in a small material.
In our study, patient levels of α-synuclein did not differ
to those found in healthy control individuals. This con-
trasts with numerous studies of the ‘core’ biomarkers,
which usually vary markedly between controls and pa-
tients with AD, and MCI to some extent. However, we
observed correlations between α-synuclein and t-tau or p-
tau among patients and controls, as reported previously
[20, 21]. A (weak) correlation between α-synuclein and
Aβ42 was only found in the control group, perhaps be-
cause both substances have physiological synaptic func-
tions [13, 38], which may have been disturbed during the
disease process. However, the correlation between α-
synuclein and Aβ40, was stronger than for other bio-
markers. This peptide is less frequently analyzed in CSF,
and the present observation in patients with AD is pos-
sibly a novel finding. Interestingly, this correlation has also
been found recently between patients with Parkinson’s
disease and healthy control individuals [39]. Aβ40 in CSF
has been found to correlate with rapid cognitive decline
[5], as has α-synuclein [17], potentially explaining the
strong correlation between them.
The present finding of a higher mean α-synuclein CSF
level at baseline in the MCI-AD group with shortest dur-
ation of initial symptoms (less than two years) is interest-
ing despite the small group size (extreme value at baseline
excluded). All patients in the MCI-AD group were similar
in that all were within two years of an AD diagnosis, so
the higher level of α-synuclein amongst those with short-
est duration since initial symptoms could be indicative of
a more rapid disease progression. A similar effect has been
observed for tau species in a larger material. Buchhave
and colleagues [40] found that early converters from MCI
to AD had increased levels of t-tau and p-tau compared to
later converters, and suggested that tau biomarkers might
reflect disease progression from MCI to AD. If so, such
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changes related to disease progression might be detectable
also in other proteins, such as α-synuclein.
Measurable α-synuclein levels are highly variable between
studies, which could be due to many reasons, including
small sample sizes, differences in characterization of patient
groups, and analytical differences [19]. The present study is
relatively small, with large individual variation in the
measured α-synuclein levels for all groups, both at baseline
(with and without the extreme value), and at follow-up. The
ELISA kit used in this study has been shown not only to
measure α-synuclein monomers, but also dimers and frag-
ments of similar size [23]. Consequently, variations in the
balance of monomers to dimers or other oligomers in CSF
between groups would not be observed with this method.
Conclusion
CSF levels of α-synuclein in a follow-up study of patients
with AD or with aMCI divided as to whether patients
progressed to AD during the two years of study or not, did
not show any significant differences in concentration com-
pared to each other over time, or to a control group at
baseline. However, CSF α-synuclein was strongly correlated
with Aβ40 (but not Aβ42), and moderately correlated with
tau species both among patients and control individuals.
Patients in the aMCI subgroup progressing to AD that had
a short duration of symptoms by the time of inclusion had
significantly higher CSF α-synuclein levels than those with
longer duration, but subgroups were small. These results
highlight the importance of knowing exactly which species
of α-synuclein are being measured by any given kit when
comparing CSF levels in different studies. According to
our results using the present method, α-synuclein is not a
potential biomarker for AD. However, other analyses deter-
mining other molecular species of α-synuclein might be
more promising.
Additional files
Additional file 1: Table S1. a) Observed group mean values
(± SD) for α-synuclein at inclusion (baseline), and after one and two years,
and b) predicted mean value (95 % CI) at baseline, together with
estimated mean change (95 % CI) from baseline values.1 (DOCX 14 kb)
Additional file 2: Table S2. Mean levels of α-synuclein in CSF at
inclusion for carriers and non- carriers of APOE ε4. (DOCX 12 kb)
a) b)
c) d)
Fig. 2 Scatterplots and line of best fit illustrating the association between α-synuclein and (a) Aβ42, (b) Aβ40, (c) total tau or (d) phosphorylated
tau measured in CSF. Points represent the total patient study material at inclusion, extreme value excluded
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